miR‐1275: A single microRNA that targets the three IGF2‐mRNA‐binding proteins hindering tumor growth in hepatocellular carcinoma

Fawzy, Injie Omar; Hamza, Mohammed Tarif; Hosny, Karim Adel; Esmat, Gamal; Tayebi, H.M. El; Abdelaziz, Ahmed Ihab

doi:10.1016/j.febslet.2015.06.038

Cited by 58 publications

(42 citation statements)

References 40 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of miR-485-5p and miR-1275 was significantly downregulated in hepatocelllular carcinoma (HCC) tissues (25,26). In particular, miR-485-5p expression was inversely correlated with TNM stage and metastasis in HCC samples (25).…”

Section: Discussionmentioning

confidence: 99%

Profiling analysis of circulating microRNA expression in cervical cancer

Nagamitsu

Nishi

Sasaki

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. MicroRNA (miRNA) expression is altered in cancer cells and is associated with the development and progression of various types of cancer. Accordingly, miRNAs may serve as diagnostic or prognostic biomarkers in cancer patients. In this study, we attempted to analyze circulating exosomal miRNA in patients with cervical cancer. Total RNA was extracted from the serum of healthy subjects, subjects with cervical intraepithelial neoplasia (CIN) and patients with cervical cancer. We first investigated miRNA expression profiles in 6 serum samples from healthy subjects and patients with cervical cancer using the miRCURY LNA microRNA array. miRNAs with significant differences in expression were validated in a larger sample set by quantitative reverse transcription-polymerase chain reaction, using TaqMan gene expression assays. The results of the miRCURY LNA microRNA array indicated that 6 of 1,223 miRNAs found in serum samples from cervical cancer patients and normal controls exhibited a >3.0-fold change in expression level in subjects with cervical cancer, with a P-value of <0.01. In a validation set (n=131) that investigated the expression of 4 of the 6 miRNAs (miR-483-5p, miR-1246, miR-1275 and miR-1290), miR-1290 was found to have significantly higher expression levels in cervical cancer samples (n=45) compared with control samples (n=31). We also found that the median levels of these miRNAs were significantly higher in subjects with cervical cancer (n=45) compared with those in subjects with CIN (n=55). Circulating miRNAs were not correlated with clinicopathological parameters. However, receiver operating characteristic curve analysis suggested that these serum miRNAs may be useful diagnostic markers in cervical cancer. The expression of circulating miR-1290 was significantly higher in the blood of cervical cancer patients compared with that in controls and may thus serve as a useful biomarker in cervical cancer diagnosis. However, larger studies are required to fully elucidate the role of circulating exosomal miRNAs in cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Profiling analysis of circulating microRNA expression in cervical cancer

Nagamitsu

Nishi

Sasaki

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…IGF2 acts primarily through IGF1 receptor (IGF1R) to exert its effect on cell signalling, particularly within a PI3K/AKT axis . In addition to its regulation of IGF2, IGF2BP2 can also directly influence the translation of IGF1 receptor (IGF1R) . Activation of IGF1R can overcome EGFR inhibition by gefitinib in HNSCC through compensatory activation of downstream AKT and ERK .…”

Section: Identification Of Pro‐oncogenic Factors In 3q26‐29mentioning

confidence: 99%

3q26‐29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes

Davidson

Shanks

2017

The FEBS Journal

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is significantly underrepresented in worldwide cancer research, yet survival rates for the disease have remained static for over 50 years. Distant metastasis is often present at the time of diagnosis, and is the primary cause of death in cancer patients. In the absence of routine effective targeted therapies, the standard of care treatment remains chemoradiation in combination with (often disfiguring) surgery. A defining characteristic of HNSCC is the amplification of a region of chromosome 3 (3q26‐29), which is consistently associated with poorer patient outcome. This review provides an overview of the role the 3q26‐29 region plays in HNSCC, in terms of both known and as yet undiscovered processes, which may have potential clinical relevance.

show abstract

“…In other researches, the abnormal expression levels of these two microRNAs were testified to promote anti-apoptosis and tumor growth (56)(57)(58). A recent study suggested that the up-regulated level of GGT was associated with the CpG island methylation in certain regains in genome, and CpG island methylation had already been reported to be correlated to tumor progression in various cancers (59).…”

Section: Ggt As a Functional Macromolecule In Mechanistic Studiesmentioning

confidence: 99%